Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LENALIDOMIDE Cause Infusion site extravasation? 11 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Infusion site extravasation have been filed in association with LENALIDOMIDE (LENALIDOMIDE). This represents 0.0% of all adverse event reports for LENALIDOMIDE.

11
Reports of Infusion site extravasation with LENALIDOMIDE
0.0%
of all LENALIDOMIDE reports
4
Deaths
7
Hospitalizations

How Dangerous Is Infusion site extravasation From LENALIDOMIDE?

Of the 11 reports, 4 (36.4%) resulted in death, 7 (63.6%) required hospitalization.

Is Infusion site extravasation Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LENALIDOMIDE. However, 11 reports have been filed with the FAERS database.

What Other Side Effects Does LENALIDOMIDE Cause?

Diarrhoea (27,576) Fatigue (22,956) Death (19,213) Off label use (17,017) Rash (15,794) Pneumonia (14,807) Plasma cell myeloma (14,191) Neuropathy peripheral (10,215) White blood cell count decreased (9,996) Constipation (9,635)

What Other Drugs Cause Infusion site extravasation?

HUMAN IMMUNOGLOBULIN G (822) INFLIXIMAB (435) INFLIXIMAB-DYYB (328) TREPROSTINIL (256) VEDOLIZUMAB (199) HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN (185) REMDESIVIR (144) FERRIC CARBOXYMALTOSE (118) RITUXIMAB (82) NATALIZUMAB (70)

Which LENALIDOMIDE Alternatives Have Lower Infusion site extravasation Risk?

LENALIDOMIDE vs LENIOLISIB LENALIDOMIDE vs LENOGRASTIM LENALIDOMIDE vs LENVATINIB LENALIDOMIDE vs LEPONEX LENALIDOMIDE vs LERCANIDIPINE

Related Pages

LENALIDOMIDE Full Profile All Infusion site extravasation Reports All Drugs Causing Infusion site extravasation LENALIDOMIDE Demographics